INTELLECTUAL AND ACADEMIC STATUS OF LONG-TERM SURVIVORS OF ACUTE LYMPHOCYTIC LEUKEM-IA (ALL).
Morris Powazek, Robert B. Rosen, Donald P i n k e l ) , City o f ope Medical Center, Long-term s u r v i v o r s of ALL ( n = 20; median 10 y e a r s ) a t City of Hope were evaluated with intelligence (WISC) a n d achievement (WRAT) tests a n d family interviews. They h a d been treated with rotational reinduction combination chemotherapy.
CNS prophylaxis h a d consisted of 2400 R c r a n i a l i r r a d . + IT Mtx (16/20) ; craniospinal i r r a d . + IT Mtx (3/20); IT Mtx (1/20) . Two children h a d experienced b a c t e r i a l meningitis, 2 seizure disorders, 1 P. c a r i n i i pneumonitis.
WlSC Verbal IQ was significantly low (mean 91.6). Poor performance on Information, Arithmetic a n d Digit Span subtests contributed to low Verbal IQ suggesting deficits i n attention, concentration, long a n d short term memory skills. WRAT achievement scores were below a v e r a g e on Spelling a n d Arithmetic subtests (mean 90.4 a n d 84.6).
8/20 h a d repeated a g r a d e .
8/20 h a d received special education o r remedial instruction a n d 4/20 h a d been tutored. The r e s u l t s indicate t h a t children with ALL i n remission a r e a t r i s k for l e a r n i n g difficulties a n d t h a t the scholastic functioning of leukemia s u r v i v o r s should be closely monitored. --Because of unexpected thrombotic complications (12 cases of cerebral i n f a r c t i o n , 4 cases of deep vein thrombosis), a comprehensive study of the hemostatic system was undertaken i n children receiving L-asp as part of ALL induction therapy. Antithrombin (AT), plasminogen (PLAS), fibrinogen (FIB), prothrombin time (PT), partial thromboplastin time (PTT), thrombin time (TT), factor V (F-V), and p l a t e l e t count were studied weekly f o r 7 weeks (wks) i n 12 children who received 9 doses of L-asp in wks 1 , 2, and 3 of induction therapy. AT, PLAS, and FIB decreased progressively i n a l l patients ( p t s ) with minimums in 3rd wk of L-asp: mean of 12 pts: 70%, 52%, and 31% of normal, respectively; lowest individual levels: 52%, 33%, and 11%, respectively. Functional and immunological assays of AT and PLAS gave identical r e s u l t s . AT and PLAS were normal 2 wks a f t e r L-asp; FIB within 3 wks. PT, PTT, and TT were prolonged during wks 1-3 and normal o r shortened by wks 5-6. P l a t e l e t production rebounded during wks 3-5 as marrow remission occurred (>400,00O/pl in 10 of 12 p t s ) . F-V rose s t e a d i l y from 112% of normal, pretherapy, t o 158% wk 5. These data demonstrate multiple abnormalities during ALL therapy; changes i n AT, PLAS, FIB, PT, PTT, and TT a r e due t o L-asp. The net e f f e c t i s a tendency t o thrombosis, which may be explained by deficiencies of AT and PLAS, rapidly r i s i n g p l a t e l e t counts, and elevated F-V, despite concurrent severe hypofibrinogenemia. Sidney Farber Cancer I n s t i t u t e , Boston, ~a s s a c h u s e t t s , and the University of Texas Medical Branch, Galveston, Texas.
Although the mortality and morbidity of CDG has been reduced by prophylactic a n t i b i o t i c s , c e r t a i n CDG patients s t i l l have a severe course leading t o death. A 15 year old white male with CDG had an acute reduction in pulmonary function (70345% of expected) and i t was decided t o transplant him with 2.4 X 108 bone marrow cellslkg from h i s HLA identical s i s t e r a f t e r preparation with rabbit anti-human thymocyte serum, procarbazine, and t o t a l body i r r a d i a t i o n (800 R). Prior t o transplantation a l l the p a t i e n t ' s peripheral blood granulocytes and bone marrow CFU-C were NBT negative while greater than 98% of the donor c e l l s were NBT positive; a f t e r BMT a1 1 hematopoietic and lymphoid elements were of donor origin; 100% of the recipients peripheral granulocytes, monocytes and bone marrow CFU-C were NBT positive. The patient developed chronic g r a f t versus host disease (GVHD) and died s i x months following transplantation of renal f a i l u r e . CDG, 1 ike other genetic disorders of bone marrow function, may be corrected by BMT in s e l e c t i v e cases. The transplant related problem of chronic GVHD i s t h e major limitation t o the increased use of BMT. ITR has emerged a s a major new problem i n children with ALL both on and off therapy. Post treatment overt ITR up t o 40% and a 10-30% incidence of occult ITR (by t e s t i c u l a r biopsy) has been reported. Our data is i n sharp contrast t o the published reports of ITR. W e have notencountered ITR a s the s o l e i n i t i a l relapse i n any of 107 boys with ALL treated a t our i n s t i t u t i o n over an 11 year period. 10 patients had mediastinal mass a t presentation and 41 had WBC >20,000/m3 a t diagnosis. A l l were treated f o r 5 yrs. with i d e n t i c a l chemotherapy. In addition, the l a s t 68 p a t i e n t s received Intermittent Intrathecal Methotrexate (MTX) and Fractional Irradiation (IMFRA) Central Nervous System (CNS) p3ophylaxis. Remission w a s induced with Vincristine (VCR) 2 mgl M , 9-Mercaptopurine (6-MP) 2.5 mglkg, and Prednisone (Pred) 60 mg/M , and y i n t a i n e d with a l t e r n a t i n g cycles of biweekly o r a l MTX 30 mg/M f o r 6 weeks, and VCR + 6-MP + Pred f o r 4 weeks.
IMFRA CNS prophylaxis is given every 10 weeks. The median dura t i o n of complete remission was 18 mos. (range 1-120 mo.) f o r patients not receiving CNS prophylaxis, and i t has not yet been reached ( >33 mos.; range 1-95 rnos.) i n those receiving CNS prophylaxis. Five of 26 p a t i e n t s off therapy had relapse, but none i n the t e s t e s . This suggests t h a t an e f f e c t i v e maintenance program such a s the r e p e t i t i v e reinduction protdcol described above Prevents ITR and that t e s t i s may not be a sanctuary s i t e .
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